SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-21-034892
Filing Date
2021-02-10
Accepted
2021-02-10 06:01:54
Documents
2
Group Members
ESSEX WOODLANDS HEALTH VENTURES FUND V, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII, L.PESSEX WOODLANDS HEALTH VENTURES FUND VIII-A, L.P.ESSEX WOODLANDS HEALTH VENTURES FUND VIII-B, L.P.ESSEX WOODLANDS HEALTH VENTURES V, L.L.C.ESSEX WOODLANDS HEALTH VEN

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d40883dsc13ga.htm SC 13G/A 231389
2 EX-99.1 d40883dex991.htm EX-99.1 27465
  Complete submission text file 0001193125-21-034892.txt   260917
Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address 1222 DEMONBREUN STREET SUITE 1001 NASHVILLE TN 37203 510-742-3400
Revance Therapeutics, Inc. (Subject) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88023 | Film No.: 21609097
SIC: 2834 Pharmaceutical Preparations

Mailing Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380
Business Address 21 WATERWAY AVENUE SUITE 225 THE WOODLANDS TX 77380 2813641555
Essex Woodlands Health Ventures VIII, L.L.C. (Filed by) CIK: 0001632027 (see all company filings)

IRS No.: 261923296
Type: SC 13G/A